Psychiatry AtlasMedication guide · United States

Sleep medicine that reduces wake signals

Lemborexant (Dayvigo)

Generic name
lemborexant
Brand names
Dayvigo
Medication class
Sleep medicine that reduces wake signals
Forms covered
Dayvigo oral tablets

Article updated: 2026-10-24 · Sources last checked: 2026-11-05

Lemborexant (Dayvigo) treats adult insomnia involving difficulty falling asleep, staying asleep or both. It blocks orexin, a brain signal that promotes wakefulness.

What to expect: The medicine is intended to help sleep on nights it is taken, but benefit varies.

Warning signs
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Insomnia with sleep-onset and/or sleep-maintenance difficulty — Adults. Pediatric safety and effectiveness are not established.Dayvigo oral tablets.

What should I expect?

The medicine is intended to help sleep on nights it is taken, but benefit varies. Assess both sleep and how alert you feel the next day.

If sleep has not improved within 7–10 days, or worsens, contact the prescriber. Persistent insomnia may have another cause; increasing the dose yourself can increase impairment.

How do I take it safely?

Take no more than once nightly, immediately before bed, only when at least seven hours remain before planned awakening. Food can delay the effect. Skip a missed dose if insufficient sleep time remains; never double or take a daytime catch-up dose.

Avoid alcohol and other sleep medicines unless specifically reviewed. Opioids, benzodiazepines and other sedatives can add impairment. Do not drive when sleepy; effects can persist beyond the dosing night.

Do not use with narcolepsy. Discuss depression, suicidal thoughts, breathing disease, falls and substance-use history. Severe liver impairment is not a recommended-use setting; other liver problems or interactions may require a lower dose.

Avoid strong or moderate CYP3A inhibitors or inducers. Even weaker inhibitors may affect the dose. Dayvigo can also reduce levels of medicines such as bupropion or methadone; a pharmacist should check both directions of interaction.

Stop and contact the prescriber immediately for sleepwalking, sleep-driving or other activity while not fully awake. Report sleep paralysis, vivid sleep-related hallucinations or sudden weakness. Keep the medicine secure and never share it.

Discuss pregnancy and breastfeeding. Low transfer into milk has been measured, but infant effects remain uncertain; monitor for excessive sedation. Pediatric use is not established, and older adults are more vulnerable to falls.

What side effects should I know about?

  • Sleepiness or fatigue is the most common adverse reaction. Nightmares, abnormal dreams or sleep paralysis can also occur.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • Stop and contact the prescriber immediately for sleepwalking, sleep-driving or other activities while not fully awake.
  • Report sleep paralysis, vivid hallucinations while falling asleep or waking, sudden muscle weakness, or dangerous next-day impairment. Do not drive while impaired.
  • New suicidal thoughts or a severe mood or behavior change needs immediate clinical contact; get emergency help if someone cannot stay safe.
  • Get emergency help for trouble breathing, swelling of the tongue or throat, collapse, a seizure or inability to wake. Suspected overdose needs immediate poison-center or emergency advice; do not wait for symptoms.

What else should I know to stay safe?

  • Do not use with narcolepsy. Review breathing disease, depression, substance-use history, falls and liver disease; severe liver impairment is not a recommended-use setting. Strong or moderate CYP3A inhibitors or inducers should be avoided, and weaker inhibitors may also require a dose change.
  • Avoid alcohol and unreviewed sedatives or other sleep medicines. Dayvigo can reduce levels of medicines such as bupropion or methadone; have the entire regimen checked. Do not drive while impaired, and store securely without sharing.
  • Discuss pregnancy and breastfeeding; low milk transfer does not establish infant safety, so watch for excessive infant sedation. Older adults are more vulnerable to falls, and pediatric use is not established.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • Reducing wake signals is a different mechanism from many sedatives, but next-day driving impairment can still occur.
  • A meal can delay the effect. Taking another tablet while waiting is unsafe.
  • Trials did not identify a withdrawal syndrome, but this does not eliminate misuse potential or mean sleep problems cannot return.

How does it work?

Lemborexant makes it harder for a wake-promoting messenger called orexin to pass its signal through the brain. Reducing that signal can make it easier to fall asleep and stay asleep. The medicine acts on a system that helps maintain waking, so its effects can also reach into the following day.

Explore medication science

How was this medicine developed?

The FDA approved Dayvigo in 2019. Its development focused on blocking both orexin receptors, with studies examining falling asleep and staying asleep. It is a Schedule IV controlled medicine.

How do I say the name?

Lemborexant: lem-boe-REX-ant. Capital letters show the stressed syllable.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. lemborexant: current US prescribing information
  2. lemborexant: FDA approval history
  3. lemborexant: patient medicine information
  4. Dayvigo: Package Insert / Prescribing Information / MOA
  5. lemborexant: FDA prescribing information
  6. daridorexant: current prescribing information
  7. Rozerem: current prescribing information
  8. Lemborexant: verified neutral parent, PubChem CID 56944144
  9. Schizophrenia
  10. NIMH: Understanding psychosis

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top